GenesisM, a joint venture between Bain Capital and Botanic Properties, broke ground on a Class A biomanufacturing facility in July of 2025 in Bedford, Mass. Designed by Perkins&Will, the sophisticated development addresses a critical need for purpose-built life sciences infrastructure in the Greater Boston region.
Sanofi opened its new U.S. headquarters in May of 2025 at M Station West in Morristown, New Jersey. Developed by SJP Properties and Scotto Properties, the seven-story, 260,000-sf facility was designed by Gensler to collocate approximately 2,000 employees with leadership roles in business operations, finance, R&D, human resources, technology, general medicines, specialty care, vaccines, and manufacturing and supply.
Gilead Sciences is constructing the Cancer Research Center in Foster City to accelerate the creation of novel solutions for pressing medical challenges. Driven by the company's enterprise master plan, the project is part of a strategic initiative to develop an internal research infrastructure that advances discovery in key focus areas and brings new technological capabilities in-house. The 182,000-sf facility was designed by Gensler to catalyze synergies between 54 clinical programs spanning oncology, inflammation, and virology.
AstraZeneca opened a $300 million cell therapy facility in May of 2025 in Rockville, Md. Developed by Alexandria Real Estate Equites, the 84,264-rsf building features specialized environments for the production of chimeric antigen receptor therapies (CAR-T) and T-cell receptor therapies (TCR-T). Next-generation biomanufacturing suites will leverage advanced process controls to create life-saving personalized medicine treatments, spanning every step from culturing and formulation to testing.
Merck broke ground in April of 2025 on a $1 billion biologics center of excellence in Wilmington, Del. Leveraging sophisticated automation solutions and artificial intelligence technologies, the 470,000-sf facility will offer laboratory, manufacturing, and logistics capabilities. The leading-edge structure will enable the launch and commercial production of next-generation biologics and therapies, including potent antibody-drug conjugates (ADCs).
Roche announced the launch of the Roche Genentech Innovation Center in March of 2025 on Harvard’s Enterprise Research Campus in Allston. With an initial lease of 30,000 sf of lab space in the first phase of construction, Roche intends to expand their R&D presence to eventually accommodate 500 employees. The initiative will bring together cardiovascular, renal, and metabolism experts with data science and AI specialists to accelerate innovation in drug discovery and development.
The 2024 SEFA Lab of the Year was awarded to the new Roche Pharma Research and Early Development (pRED) Center in Basel, Switzerland, that opened in September 2024 as a state-of-the-art research center dedicated to the discovery and development of groundbreaking drugs. The pRED Center exemplifies the future of transformative research by fostering innovation and collaboration, and embodying Roche’s commitment to advancing global healthcare and delivering life-changing treatments.
An evolution of the equipment and technology researchers need is transforming ordinary labs into facilities that deserve to be called next-generation or future-ready. Significant changes in space utilization and lab planning and design are driven by increased automation and robotics, the incorporation of manufacturing, enhanced information technology with an emphasis on data collection, ever-evolving technologies, developer core/shell fit-outs, hybrid work patterns, and different approaches to project delivery and construction.
Moderna completed construction on a £150 million complex in the United Kingdom for the discovery and production of mRNA vaccines and therapeutics for COVID-19 and emerging respiratory health threats. Located on the Harwell Campus in Oxfordshire, the Moderna Innovation and Technology Centre (MITC) comprises two 145,000-sf buildings for research, development, and manufacturing.
BioMed Realty is constructing a 637,000-sf life sciences facility in Cambridge for Takeda Pharmaceuticals. Designed by CBT Architects, the 16-story structure will provide advanced lab and office environments to accelerate the creation of innovative therapies and vaccines. Featuring flexible spaces to optimize in-person interaction and connection in a hybrid working model, the leased building furthers Takeda’s goal of unifying their Global R&D Center in Kendall Square.
The past few decades have brought myriad technological changes to our daily lives, and experts predict the pace of change will only increase—especially in the use of artificial intelligence (AI) tools. Much of the talk surrounding AI focuses on automating repetitive processes and analyzing data, which require additional computational power but not necessarily structural modifications. But emerging technologies, including AI and robotics, may require universities and companies to rethink their approach to designing and planning buildings and labs.
The fast-moving nature of biotechnology innovation means architects and designers for Regeneron have to plan for researchers’ requirements to change by the time new laboratories open on the Tarrytown, N.Y., campus. The campus is undergoing a $1.8 billion expansion, adding 900,000 sf of new laboratory and office space, along with additional parking, amenities, and infrastructure to support research and development.
Kadans Science Partner is constructing a 139,000-sf facility in Cambridge in the United Kingdom that will catalyze the discovery of new therapies, medical devices, and digital healthcare solutions. Providing fully fitted, best-in-class research environments, Merlin Place will offer CL2 wet labs, dry labs, and dedicated office spaces. A flexible structural grid with adaptable floor heights will support a range of configurations in the building, which will utilize a modular layout to accommodate multiple tenants or a single entity.
Breakthrough Properties celebrated the opening of a 510,000-sf life sciences campus in San Diego in October of 2024. Designed by Flad Architects, Torrey View by Breakthrough offers state-of-the-art wet labs for the development of novel therapies and technologies, as well as flexible workspaces and collaboration areas. An iconic tessellated envelope allows interior floor plates to be infused with natural light, maximizing occupant wellness and energy efficiency without compromising performance.
Takeda Pharmaceuticals and Boston Medical Center (BMC) have initiated a strategic research collaboration to decarbonize the value chain throughout the healthcare ecosystem. One of the most difficult environmental challenges facing the industry today is greenhouse gas (GHG) emissions released from the disposal of regulated medical waste, including pharmaceutical packaging and single-use plastics. A key objective of this analysis is to effectively identify, pilot, and share decarbonization solutions that other healthcare organizations can adopt.
